Date de publication: 26 août 2019
Promoteur – Intermédiaire Financier
AMW GMBHLieu
Description
AMW is a pharmaceutical company specialized in the development and manufacturing of innovative drug delivery systems, i.e. technologies aimed at the targeted delivery and controlled release of pharmaceutical compounds in order to improve their efficacy, safety and convenience. The company has a broad and diversified development pipeline, focused on providing solutions in strongly growing indications such as oncology, neurology, pain therapy and dermatology, which is expected to drive significant revenue growth in the future.
Objectifs
The project will cover the company's substantial Research & Development (R&D) expenses relating to the development of existing and new products It will also include an additional R&D facility and purpose-built manufacturing technologies for innovative drug delivery systems together with associated laboratory and manufacturing equipment.
Commentaires
Loan foreseen under the European Fund for Strategic Investments (EFSI).
Secteur(s)
- Services - Activités spécialisées, scientifiques et techniques
Montant BEI envisagé (montant approximatif)
EUR 25 million
Coût total (montant approximatif)
EUR 52 million
Aspects environnementaux
The promoter's investments concern research, development and innovation activities that will be mainly carried out in existing facilities already authorised for similar activities and volumes and as such, do not require an Environmental Impact Assessment (EIA), according to the relevant EU Directives. However the Bank's services will verify during appraisal whether an EIA is required, as well as the screening decision of the competent authority.
Passation des marchés
The promoter is a private company not operating in the utilities sector and not having a status of a contracting authority. Thus, it is not covered by the EU directives on procurement.
Statut
Signé - 8/11/2017
Clause de non-responsabilité
Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).